Genomes and Genes
Mary A Marovich
Affiliation: Division of Retrovirology
- Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cellsMary A Marovich
Division of Retrovirology, US Military HIV Research Program, Rockville, Maryland 20850, USA
J Infect Dis 186:1242-52. 2002..These data support an ongoing HIV vaccine trial comparing conventional vaccine delivery routes with ex vivo vaccine-loaded autologous DCs for immunogenicity in HIV-1-uninfected volunteers...
- ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine developmentMary A Marovich
Division of Retrovirology, US Military HIV Research Program, Rockville, Maryland 20850, USA
Expert Rev Vaccines 3:S99-104. 2004..All of these observations have important implications for the future of HIV vaccines and need to be considered in the design of the next generation of products...
- A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cellsMichael A Eller
U S Military HIV Research Program, Rockville, Maryland, United States of America
PLoS ONE 6:e24254. 2011..We explored the concept that direct ex vivo targeting of human dendritic cells (DC) would enhance the immune response compared to either conventional intramuscular or intradermal injections of the vaccine alone...
- Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatmentM A Marovich
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Clin Infect Dis 33:1076-9. 2001..Combination therapy with intralesional sodium stibogluconate and oral itraconazole was successful and immunologic data suggest that both CD4(+) and CD8(+) T cell subsets had roles in this disease process...
- DC-SIGN (CD209) mediates dengue virus infection of human dendritic cellsBoonrat Tassaneetrithep
Division of Retrovirology, Walter Reed Army Institite of Research and Henry M Jackson Foundation for the Advancement of Military Medicine Diseases, Rockville, MD 20850, USA
J Exp Med 197:823-9. 2003..Viruses produced by dendritic cells are infectious for DC-SIGN- and L-SIGN-bearing THP-1 cells and other permissive cell lines. Therefore, DC-SIGN may be considered as a new target for designing therapies that block dengue infection...
- Human dendritic cells as targets of dengue virus infectionM Marovich
Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation, Rockville, Maryland 20850, USA
J Investig Dermatol Symp Proc 6:219-24. 2001..Immature dendritic cells exposed to dengue virus produce TNF-alpha protein. Some of these immature dendritic cells undergo TNF-alpha mediated maturation as a consequence of exposure to the dengue virus...
- Role of dendritic cells in antibody-dependent enhancement of dengue virus infectionKobporn Boonnak
Department of Medicine, Uniformed Services University of the Health Sciences, Division of Retrovirology, Department of Vaccine R and D, Walter Reed Army Institute of Research, 13 Taft Ct, Suite 200, Rockville, MD 20850, USA
J Virol 82:3939-51. 2008..Studying the cellular targets of DV infection and their susceptibility to ADE will aid our understanding of complex disease and contribute to the field of vaccine development...
- Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim
United States Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, Maryland, USA
PLoS ONE 7:e45840. 2012..This study supports the rationale for testing heterologous prime-boost regimens in humans...
- Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infectionKobporn Boonnak
Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland 20850, USA
J Virol 85:1671-83. 2011..Our data suggest that ADE effects are cell type specific, are influenced by host genetics, and, depending on relative infection rates, may further contribute to the complexity of DV pathogenesis...
- Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier
United States Military HIV Research Program, Rockville, Maryland, United States of America
PLoS ONE 5:e13983. 2010..The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand...
- Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccinesPatricia L Earl
Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA
Vaccine 27:5885-95. 2009..The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted...
- Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infectionMichael A Eller
U S Military HIV Research Program, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
J Acquir Immune Defic Syndr 61:9-18. 2012..To study the possible role of T cells associated with better outcome, we examined CD4 and CD8 T-cell responses against HIV-1 and cytomegalovirus (CMV) in Ugandans infected with subtype A HIV-1...
- Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infectionKobporn Boonnak
Division of Retrovirology, Henry M Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research, Rockville, MD 20850, USA
J Immunol 190:5659-65. 2013....
- Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentJeffrey R Currier
U S Military HIV Research Program, Rockville, Maryland 20850, USA
Clin Vaccine Immunol 15:267-76. 2008..We propose a simple schema of biological QA/QC protocols to augment the standard biochemical QA/QC analyses as a means to circumvent this and other problems that can affect cellular immune-based assay outcome and interpretation...
- Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell poolingLindsay Wieczorek
Military HIV Research Program, Silver Spring, MD, USA Henry M Jackson Foundation, Bethesda, MD, USA
Virology 447:240-8. 2013....
- Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoireNicholas J Steers
Henry Jackson Foundation for the Advancement of Military Medicine, 1600 East Gude Drive, Rockville, Maryland 20850, USA
J Virol 85:1541-53. 2011..These epitopes have been linked to HIV-1 disease progression. Our results suggest that the source of generation of precursor MHC class I epitopes may be a critical factor for the induction of relevant epitope-specific cytotoxic T cells...
- Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motifMichael A Eller
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
J Virol 85:4802-11. 2011..These results indicate that chronic HIV-1 infection is associated with increased NK cell polyfunctionality and elevated levels of KIR3DL1(+) NK cells in Ugandans carrying the HLA-B Bw4 motif...
- Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applicationsJeffrey R Currier
US Military HIV Research Program MHRP, Rockville, MD, USA
J Transl Med 9:212. 2011..Assessment of potential HIV strain coverage by candidate T cell-based vaccines (whether natural sequence or computationally optimized products) is now a critical component in interpreting candidate vaccine suitability...
- Differential effects of dengue virus on infected and bystander dendritic cellsDupeh R Palmer
Department of Viral Diseases, Walter Reed Army Institute of Research, Naval Research Center, Silver Spring, Maryland, USA
J Virol 79:2432-9. 2005..Taken together, these results constitute an immune evasion strategy used by DV that directly impairs antigen-presenting cell function by maturation blockade and induction of apoptosis...
- A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infectionNaomi E Aronson
Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
PLoS Negl Trop Dis 4:e628. 2010..Cutaneous Leishmania major has affected many travelers including military personnel in Iraq and Afghanistan. Optimal treatment for this localized infection has not been defined, but interestingly the parasite is thermosensitive...
- An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodiesNicole C Martin
Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
J Virol Methods 134:74-85. 2006..Importantly, serotype-specific neutralizing activity against recently isolated dengue strains with less heterotypic cross-neutralization than laboratory adapted viruses was also demonstrated...
- Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central AfricaLydie Beniguel
CGIMAP EA3064, Faculte de Medecine, Université Jean Monnet, 15 Rue A Paré 42023, Saint Etienne Cedex 2, France
Clin Dev Immunol 11:23-7. 2004..It may impact the management of HIV infection in countries with limited access to HIV drugs and urges consideration for implementation of therapeutic vaccines...
- Specific antibody production by blood B cells is retained in late stage drug-naïve HIV-infected AfricansLydie Beniguel
GIMAP EA3064, Faculte de Medecine, université J Monnet, St Etienne, France
Clin Dev Immunol 11:121-7. 2004....